Blue Jet Healthcare Ltd is set to break ground on a ₹2,300 crore greenfield pharmaceutical manufacturing facility at Rambilli Industrial Park in Anakapalli district, Andhra Pradesh. With this investment, the company aims to significantly expand its specialty chemicals and Contract Development and Manufacturing Organisation (CDMO) capabilities in India.
102-Acre Facility to Boost Specialty Manufacturing
The upcoming plant will span 102 acres and will manufacture contrast media intermediates, high-intensity sweeteners, and multipurpose chemistry products. The company will develop the facility in phases, with commercial operations expected to begin by FY2028–29. The expansion marks a major step in scaling up high-value pharmaceutical intermediates. It will strengthen India’s position in the global pharma supply chain.
Strengthening Global CDMO Footprint
Founded in 1968 as Jet Chemicals Pvt Ltd, Blue Jet Healthcare has evolved into an integrated CDMO supplying advanced pharmaceutical intermediates and APIs across India, Europe, and the United States. Notably, the company is a key global player in contrast media intermediates and was among the early manufacturers of saccharin in India. Over the years, it has built strong process chemistry capabilities, scale-up expertise, and regulatory-compliant manufacturing systems. Through the Rambilli project, the company plans to deepen engagement with multinational pharmaceutical clients. These clients are seeking supply-chain diversification beyond single geographies.
ESG-Focused, Sustainable Manufacturing
Importantly, the new facility will integrate advanced sustainability features. The plant will incorporate zero liquid discharge (ZLD) technology along with an advanced effluent treatment system connected to marine discharge infrastructure. The company designed the system to reduce energy consumption by nearly 70 percent and recover 90–95 percent of wastewater. As global pharmaceutical companies tighten ESG benchmarks and environmental compliance requirements. This approach positions Blue Jet Healthcare as a responsible and future-ready manufacturing partner.
Leadership Driving Long-Term Growth
Under the leadership of Executive Chairman Akshay Bansarilal Arora and Managing Director Shiven Akshay Arora, the company is strengthening its growth strategy. It continues to focus on high-value specialty intermediates and sustainable pharma manufacturing. As reported by manufacturingtodayindia.com, the ₹2,300 crore investment underscores Blue Jet Healthcare’s long-term growth strategy. It also reinforces Andhra Pradesh’s emergence as a major pharmaceutical manufacturing hub.
